OneDigital Investment Advisors LLC Takes $1.27 Million Position in Edwards Lifesciences Corporation $EW

OneDigital Investment Advisors LLC acquired a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW) in the second quarter, HoldingsChannel reports. The fund acquired 14,060 shares of the medical research company’s stock, valued at approximately $1,272,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Hanson & Doremus Investment Management bought a new position in Edwards Lifesciences in the first quarter worth about $25,000. JPL Wealth Management LLC bought a new position in shares of Edwards Lifesciences during the third quarter valued at approximately $25,000. MV Capital Management Inc. acquired a new stake in shares of Edwards Lifesciences during the 4th quarter worth approximately $26,000. RMG Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences during the 1st quarter worth approximately $26,000. Finally, Kemnay Advisory Services Inc. bought a new stake in shares of Edwards Lifesciences in the 4th quarter worth approximately $27,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total transaction of $56,966.57. Following the sale, the vice president directly owned 40,034 shares in the company, valued at approximately $3,684,329.02. The trade was a 1.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the company’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the sale, the senior vice president directly owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. This represents a 3.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 25,570 shares of company stock worth $2,219,390 in the last 90 days. Corporate insiders own 0.31% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Royal Bank Of Canada boosted their price objective on Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. UBS Group began coverage on Edwards Lifesciences in a research report on Tuesday, July 28th. They issued a “buy” rating and a $110.00 target price on the stock. TD Cowen reiterated a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. Leerink Partners raised shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $87.00 to $101.00 in a report on Friday, July 24th. Finally, Piper Sandler restated an “overweight” rating and set a $101.00 price target (up from $100.00) on shares of Edwards Lifesciences in a research report on Friday, July 24th. Seventeen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $100.27.

Edwards Lifesciences Trading Down 0.8%

Shares of EW stock opened at $90.84 on Tuesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $96.29. The stock has a fifty day moving average of $88.83 and a two-hundred day moving average of $84.43. The firm has a market capitalization of $52.31 billion, a PE ratio of 52.21, a price-to-earnings-growth ratio of 2.30 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.04. The company had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The company’s revenue for the quarter was up 13.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, research analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.